Status:
COMPLETED
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to assess the safety and tolerability of ascending multiple oral doses of HCV-796 in healthy Japanese male subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00385190
Start Date
July 1 2006
End Date
December 1 2006
Last Update
August 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minato-ku, Tokyo, Japan, 108-8642